entertainment -WSS

entertainment

author：focus 2025-10-01 10:57:22 - browse：432

Eli Lilly headquarters — Kristoffer Tripplaar/AP

SAN DIEGO – An experimental pill from Eli Lilly led to 14.7% weight loss on the highest dose in a 36-week trial, heating up the growing competition among drugmakers to develop an effective oral obesity therapy.

The mid-stage results for orforglipron match the estimates of 14-15% weight loss that Lilly gave in an investor call late last year. The full results, published Friday in the New England Journal of Medicine, were presented here to a packed conference room at the American Diabetes Association conference.

By the end of trial, the authors said, participants’ weight loss had not plateaued, suggesting potential for even greater weight loss over a longer treatment period.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Readout Newsletter: GSK, Viking Therapeutics, mifepristone news

WSS

Ohio train derailment: Experts on toxic chemical risks

Websites selling Wegovy, Zepbound ingredients targeted by FDA

Medicare Advantage isn’t working — for anyone

Bernie Sanders gets little from pharma CEOs on drug prices

Redefining sustainability for the pharmaceutical industry

Childhood vaccination ad campaign launches in the U.K.

explore

entertainment

hotspot

Medical leaders decry Supreme Court decision on affirmative action

'Vaccine

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Resistance to opioid

After affirmative action ruling, medical educators look to 'holistic review'

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

Supreme Court strikes down use of affirmative action

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

United colonoscopy coverage change 'may cost lives,' doctors say

Congress considering partial increase for doctor pay in Medicare

hotspot

Here’s what’s in the FDA plan to include pregnant women in clinical trials

Elisabeth Bik tackles the widespread issue of research misconduct

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Resistance to opioid

Laying a path for careers in science

Elisabeth Bik tackles the widespread issue of research misconduct

hotspot

hotspot

focus

focus